Splet一篇2024年发表于Cancer Cell上的论文“Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple negative breast cancer”利用单细胞转录组测序（scRNA-seq）、单细胞T细胞受体序列测序（scTCR-seq）和单细胞染色质可及性测序（scATAC-seq）等技术，对 ... Splet09. nov. 2024 · A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer. Histopathology. 2024;78:567–77. Li Y, Vennapusa B, Chang CW, et al. Prevalence study of PD-L1 SP142 assay in metastatic triple-negative breast …
Overview Atezolizumab with nab-paclitaxel for untreated PD-L1 ...
SpletInteractions between programmed death-1 (PD-1) with its ligand PD-L1 on tumor cells can antagonize T cell responses. Inhibiting these interactions using immune checkpoint … SpletIntroduction. Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by absence of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) and represents about 15%–20% of all breast cancer. 1 TNBC patients often present with visceral involvement and typically show rapid … psalms ajayi
Advancing immunotherapy for early-stage triple-negative breast cancer …
SpletA PD-L1 test uses a sample of cancerous tumor tissue to measure how much of a protein called PD-L1 is found on the cancer cells. If you have certain types of cancer, PD-L1 testing can check whether you may benefit from a type of cancer treatment called immunotherapy. Immunotherapy helps your own immune system fight cancer. Spletpred toliko dnevi: 2 · Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer Nat Commun. 2024 Apr 13 ... (PD-L1) expressing … Splet22. okt. 2024 · Objective: To study the expression of programmed cell death ligand-1 (PD-L1) and breast cancer susceptibility gene 1 (BRCA1) in triple-negative breast cancer … banyan apartments